Organon (OGN) Other Non Operating Income (2020 - 2026)
Organon (OGN) posted quarterly Other Non Operating Income of $96.0 million for Q1 2026, up 2300.0% year-over-year from $4.0 million in Q1 2025, and up 243.28% on a QoQ basis from -$67.0 million in Q4 2025.
Organon (OGN) Other Non Operating Income (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Other Non Operating Income for 7 consecutive years, with $96.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 2300.0% year-over-year to $96.0 million; the TTM figure through Mar 2026 stood at $60.0 million (up 957.14% YoY), while the FY2025 annual figure was -$14.0 million, up 33.33% from the prior year.
- Other Non Operating Income came in at $96.0 million for Q1 2026 at Organon, up from -$67.0 million in the prior quarter.
- The five-year high for Other Non Operating Income was $96.0 million in Q1 2026, with the low at -$67.0 million in Q4 2025.
- Average Other Non Operating Income over 5 years is $1.6 million, with a median of -$3.0 million recorded in 2022.
- Across the five-year window, Other Non Operating Income slumped 1700.0% in 2022 and soared 2300.0% in 2026, its largest moves.
- Year by year, Other Non Operating Income stood at -$32.0 million in 2022, then jumped by 131.25% to $10.0 million in 2023, then plunged by 220.0% to -$12.0 million in 2024, then slumped by 458.33% to -$67.0 million in 2025, then surged by 243.28% to $96.0 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $96.0 million, -$67.0 million, and $30.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.00 Mn |
| Dec 31, 2025 | -67.00 Mn |
| Sep 30, 2025 | 30.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Dec 31, 2024 | -12.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | -6.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -6.00 Mn |
| Dec 31, 2022 | -32.00 Mn |
| Sep 30, 2022 | -4.00 Mn |
| Jun 30, 2022 | 21.00 Mn |
| Mar 31, 2022 | -4.00 Mn |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | -1.00 Mn |
| Jun 30, 2021 | -20.00 Mn |
| Mar 31, 2021 | 2.00 Mn |